UPCC 15120: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastat
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to find out if capivasertib given with paclitaxel is an effective treatment for triple negative breast cancer (TNBC). As part of this study subjects will receive paclitaxel in combination with either capivasertib or a placebo. Eligible subjects will be those diagnosed with metastatic (or locally advanced and inoperable) TNBC.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 844280
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
